Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
2nd Annual Congress on Neurology and Epidemiology
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.

Pages